CRL vs IPCXR · rev $4.02B vs rev $100.0M
Charles River Laboratories (CRL) versus Inflection Point Acquisition Corp. III Rights (IPCXR) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Inflection Point Acquisition Corp. III Rights (IPCXR) common stock listed on US.
Latest reported CRL revenue for 2025-12-27 was $4.02B. Net income was -$144.3M. CRL currently screens at market cap $7.78B.
Latest reported IPCXR revenue for 2025-09-30 was $100.0M. Net income was -$90.8K. IPCXR currently screens at market cap $0.
CRL currently screens at market cap $7.78B. IPCXR currently screens at market cap $0.
Not investment advice. Open the CRL and IPCXR stock pages for the full models.
Not investment advice.